Natera, Inc. Stock price

Equities

NTRA

US6323071042

Healthcare Facilities & Services

Real-time Estimate Cboe BZX 03:18:12 2024-03-28 pm EDT 5-day change 1st Jan Change
91.32 USD +0.95% Intraday chart for Natera, Inc. -0.82% +45.47%
Sales 2024 * 1.34B Sales 2025 * 1.58B Capitalization 10.92B
Net income 2024 * -282M Net income 2025 * -147M EV / Sales 2024 * 7.85 x
Net cash position 2024 * 414M Net cash position 2025 * 508M EV / Sales 2025 * 6.58 x
P/E ratio 2024 *
-38.8 x
P/E ratio 2025 *
-74.9 x
Employees 3,288
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.15%
More Fundamentals * Assessed data
Dynamic Chart
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer CI
Natera Insider Sold Shares Worth $534,331, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $824,092, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $16,694,485, According to a Recent SEC Filing MT
Natera Receives Commercial Insurance Coverage of Genetic Test for Transplant Risks MT
Piper Sandler Raises Natera's Price Target to $110 From $70, Maintains Overweight Rating MT
Transcript : Natera, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-06-2024 09:50 AM
Transcript : Natera, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 02:15 PM
Natera Insider Sold Shares Worth $4,478,268, According to a Recent SEC Filing MT
UBS Adjusts Natera Price Target to $104 From $70, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Natera to $100 From $87, Maintains Buy Rating MT
Natera Narrows Q4 Loss, Revenue Rises; Shares Rise Late as 2024 Revenue Outlook Beats Consensus MT
Transcript : Natera, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (NTRA) NATERA Posts Q4 Revenue $311.1M, vs. Street Est of $287.3M MT
Natera Guides For 2024 Revenue of $1.32-$1.35 Billion, vs CIQ Analyst Consensus of $1.27 Billion MT
More news
1 day+0.51%
1 week-2.63%
Current month+4.59%
1 month+18.78%
3 months+47.76%
6 months+94.04%
Current year+44.41%
More quotes
1 week
87.89
Extreme 87.89
93.00
1 month
83.77
Extreme 83.77
96.24
Current year
58.53
Extreme 58.53
96.24
1 year
36.90
Extreme 36.9
96.24
3 years
26.10
Extreme 26.1
129.09
5 years
16.87
Extreme 16.87
129.09
10 years
6.52
Extreme 6.52
129.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 10-11-30
Founder 51 03-10-31
Founder 51 03-10-31
Members of the board TitleAgeSince
Director/Board Member 58 14-10-31
Director/Board Member 50 06-12-31
Director/Board Member 76 14-01-31
More insiders
Date Price Change Volume
24-03-28 91.14 +0.75% 555 315
24-03-27 90.46 +0.51% 1,617,256
24-03-26 90 -1.52% 1,391,625
24-03-25 91.39 -1.01% 1,067,024
24-03-22 92.32 +0.49% 452,364

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Natera, Inc. is a diagnostics company that is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women's health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Preimplantation Genetics, Anora Miscarriage Test (Anora) and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company's algorithms and bioinformatics in order to validate and launch tests based on the Company's technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
90.46 USD
Average target price
95.41 USD
Spread / Average Target
+5.47%
Consensus
  1. Stock
  2. Equities
  3. Stock Natera, Inc. - Nasdaq